Items Tagged ‘Multiple Myeloma’

April 25th, 2017

Revlimid Maintenance Therapy Related to More Secondary Primary Malignancies in Older Adults

By

Results from a pivotal clinical trial have supported the use of Revlimid (lenalidomide) as maintenance therapy for patients multiple myeloma.  A new analysis from the trial just published in the Journal, Blood raises concerns about the safety of Revlimd maintenance reporting an increased risk of developing secondary cancer. Doctors from the Institute of Cancer Research […]

View full entry

Tags: maintenance therapy, Multiple Myeloma, News, revlimid


March 28th, 2017

FDA Expands Indication for Revlimid® as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant

By

The U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid® (lenalidomide) to include use for patients with multiple myeloma as maintenance therapy following autologous stem cell transplant (ASCT). The expanded indication makes Revlimid® the first and only treatment to receive FDA approval for maintenance use following auto-HSCT.1 Autologous stem cell transplant after […]

View full entry

Tags: maintenance, Multiple Myeloma, News, revlimid, secondary cancer, secondary malignancy


March 22nd, 2017

Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma

By

The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi.  The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival compared to Velcade (Bortezomib), but also overall improved overall survival, making it a clinically meaningful advance in the treatment of relapsed or refractory multiple myeloma.  Patients with relapsed […]

View full entry

Tags: kyprolis, Multiple Myeloma, News, proteosome inhibitors


December 1st, 2016

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

By

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published in the New England Journal of Medicine. Many patients with cancer require red blood cell transfusions, either in response to the disease itself, or […]

View full entry

Tags: Blood transfusions, Hodgkin's Lymphoma, Leukemia, long-term, Multiple Myeloma, Myeloproliferative Neoplasms MPN, News, Non-Hodgkin's Lymphoma, short-term, storage


November 29th, 2016

Darzalex® Approved for Additional Indications in Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used in combination with lenalidomide and dexamethasone, or in combination with bortezomib and dexamethasone. Daratumumab is already approved […]

View full entry

Tags: blood cancer, bortezomib, CASTOR, CD38, Darzalex, dexamethasone, fda, lenalidomide, Multiple Myeloma, News, POLLUX, Recurrent Multiple Myeloma


October 12th, 2016

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma

By

A large, comparative, phase III HOVON clinical trial recently confirmed that upfront autologous stem cell transplantation (ASCT) should still be the treatment of choice in younger patients with newly diagnosed multiple myeloma (MM). The findings of this trial clearly demonstrated that ASCT should remain the preferred treatment for younger patients with MM. The clinical trial […]

View full entry

Tags: ASCT, bortezomib, clinical trial, cyclophosphamide, dexamethasone, HOVON, Multiple Myeloma, News, Stem Cell Transplant, velcade


July 7th, 2016

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma

By

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells produce proteins called antibodies that […]

View full entry

Tags: blood cancer, daratumumab, Darxalex, IMid, Multiple Myeloma, News, PI, proteasome inhibitor, Recurrent Multiple Myeloma, Stages II-III Multiple Myeloma


April 21st, 2016

Aplidin® Improves Progression-Free Survival in Multiple Myeloma

By

The addition of the investigative agent Aplidin® (plitidepsin) to dexamethasone appears to significantly reduce the risk of cancer progression or death compared to dexamethasone alone among patients with multiple myeloma that has progressed following prior therapies. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells […]

View full entry

Tags: ADMYRE, Aplidin, ascidian Aplidium albicans, blood cancer, Multiple Myeloma, News, plasma cells, Plitidepsin, Recurrent Multiple Myeloma


March 30th, 2016

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant

By

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio is the first approved treatment for severe hepatic VOD. Hepatic VOD is a rare, but life-threatening complication that can occur following chemotherapy and a stem cell transplant (SCT) […]

View full entry

Tags: Chemotherapy, chemotherpay, hepatic VOC, Hodgkin's Lymphoma, HSCT, Leukemia, Lymphoma, Multiple Myeloma, News, Non-Hodgkin's Lymphoma, Stem Cell Transplant


January 26th, 2016

Combo Therapy of Kyprolis plus Dexamethasone Approved for Recurrent Multiple Myeloma

By

The United States Food and Drug Administration (FDA) recently approved a new treatment combination consisting of Kyprolis (carfilzomib) plus dexamethasone for patients with relapsed or refractory multiple myeloma. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells produce proteins called antibodies that are an important […]

View full entry

Tags: carfilzomib, dexamethasone, ENDEAVOR, fda, kyprolis, Multiple Myeloma, News, Recurrent Multiple Myeloma


December 31st, 2015

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings

By

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH) Annual Meeting, in Orlando, December 5-8, made it increasingly clear that new discoveries […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, all, AML, ASH, blood cancer, CAR T, Chronic Lymphocytic Leukemia, CLL, fda, Leukemia, Lymphoma


December 21st, 2015

Addition of Velcade® to Revlimid®/Dexamethasone Improves Survival in Newly Diagnosed Multiple Myeloma

By

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma among patients who do not intend to immediately undergo a stem cell transplant. These results were presented at the 2015 annual meeting of the American Society of Hematology in […]

View full entry

Tags: bortezomib, Multiple Myeloma, News, revlimid, velcade


December 7th, 2015

FDA Approves Empliciti for Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for the treatment of patients with multiple myeloma who have received prior therapies. The indication specifies that Empliciti is to be used in combination with lenalidomide and dexamethasone for the treatment of patients who have received one to three prior therapies for multiple […]

View full entry

Tags: dexamethasone, elotuzumab, Empliciti, fda, lenalidomide, Multiple Myeloma, News, Recurrent Multiple Myeloma, SLAMF7


November 23rd, 2015

Ninlaro® Approved for Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has granted approval to Ninlaro® (ixazomib) for the treatment of multiple myeloma. This marks the third drug approved this year for the treatment of multiple myeloma. The approval specifies that Ninlaro is to be used in addition to two other agents, Revlimid (lenalidomide) and dexamethasone, to treat […]

View full entry

Tags: fda, Multiple Myeloma, News, ninlaro, Recurrent Multiple Myeloma


November 17th, 2015

FDA Approves Darzalex Providing a New Treatment for Patients with Multiple Myeloma

By

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma. Darzalex is the first monoclonal antibody approved for treating multiple myeloma. Darzalex appears to be effective in patients with multiple myeloma that has stopped responding to standard therapies according to study results recently published in the […]

View full entry

Tags: Darzlex, monoclonal antibody, Multiple Myeloma, News, Recurrent Multiple Myeloma